Lifestance Health Group (LFST) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual Meeting scheduled for June 2, 2026, will be held virtually to maximize shareholder participation and accessibility.
Shareholders will vote on director elections, auditor ratification, executive compensation, and other business.
Proxy materials and annual report are available online, with multiple voting methods provided.
Voting matters and shareholder proposals
Shareholders will elect two directors to serve until 2029.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is on the agenda.
Advisory vote on executive compensation for named executive officers.
Shareholders may submit proposals for future meetings, subject to deadlines and requirements.
Board of directors and corporate governance
Board is divided into three classes with staggered terms to ensure continuity and stability.
Board size will be reduced to eight members after the meeting.
Majority of directors are independent under Nasdaq rules.
Board committees include audit, compensation, nominating/governance, and quality/compliance, each with defined responsibilities.
Annual board and committee performance reviews are conducted.
Sponsor Investors (TPG and Summit) retain nomination rights for board seats based on ownership levels.
Latest events from Lifestance Health Group
- Director elections, auditor ratification, and say-on-pay top the agenda for the virtual annual meeting.LFST
Proxy filing23 Apr 2026 - 2025 delivered strong growth and margins, with 2026 guidance projecting further expansion and $100M buyback.LFST
Q4 202525 Feb 2026 - Q2 revenue up 20%, Adjusted EBITDA doubled, and guidance raised for 2024.LFST
Q2 20242 Feb 2026 - Margin expansion and strategic M&A set to drive growth beyond 2025, despite near-term payer headwinds.LFST
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Hybrid care, operational discipline, and payer wins fuel growth and margin expansion.LFST
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue up 19% to $312.7M, net loss narrowed, and guidance raised for key metrics.LFST
Q3 202416 Jan 2026 - Revenue up 19% and Adjusted EBITDA more than doubled, with strong 2025 growth outlook.LFST
Q4 202419 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve executive pay amid strong 2024 results.LFST
Proxy Filing1 Dec 2025 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.LFST
Proxy Filing1 Dec 2025